Hepatitis A historical perspective: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
| Line 11: | Line 11: | ||
The costs associated with hepatitis A are substantial. Surveillance data indicate that 11%-22% of persons with hepatitis A are hospitalized.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4812a1.htm CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37]</ref> The average duration of work loss for adults who become ill has been estimated at 15.5 days for nonhospitalized patients and 33.2 days for hospitalized patients.<ref name="pmid10655272">{{cite journal |author=Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M |title=The cost of hepatitis A infections in American adolescents and adults in 1997 |journal=[[Hepatology (Baltimore, Md.)]] |volume=31 |issue=2 |pages=469–73 |year=2000 |month=February |pmid=10655272 |doi=10.1002/hep.510310229 |url=http://dx.doi.org/10.1002/hep.510310229 |accessdate=2012-02-28}}</ref> Estimates of the annual direct and indirect costs of hepatitis A in the United States have ranged from $300 million to $488.8 million in 1997 dollars.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4812a1.htm CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37]</ref><ref name="pmid10655272">{{cite journal |author=Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M |title=The cost of hepatitis A infections in American adolescents and adults in 1997 |journal=[[Hepatology (Baltimore, Md.)]] |volume=31 |issue=2 |pages=469–73 |year=2000 |month=February |pmid=10655272 |doi=10.1002/hep.510310229 |url=http://dx.doi.org/10.1002/hep.510310229 |accessdate=2012-02-28}}</ref> A recent Markov model analysis estimated economic costs of $133.5 million during the lifetime of a single age cohort of children born in 2005, in the absence of vaccination. | The costs associated with hepatitis A are substantial. Surveillance data indicate that 11%-22% of persons with hepatitis A are hospitalized.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4812a1.htm CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37]</ref> The average duration of work loss for adults who become ill has been estimated at 15.5 days for nonhospitalized patients and 33.2 days for hospitalized patients.<ref name="pmid10655272">{{cite journal |author=Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M |title=The cost of hepatitis A infections in American adolescents and adults in 1997 |journal=[[Hepatology (Baltimore, Md.)]] |volume=31 |issue=2 |pages=469–73 |year=2000 |month=February |pmid=10655272 |doi=10.1002/hep.510310229 |url=http://dx.doi.org/10.1002/hep.510310229 |accessdate=2012-02-28}}</ref> Estimates of the annual direct and indirect costs of hepatitis A in the United States have ranged from $300 million to $488.8 million in 1997 dollars.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4812a1.htm CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37]</ref><ref name="pmid10655272">{{cite journal |author=Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M |title=The cost of hepatitis A infections in American adolescents and adults in 1997 |journal=[[Hepatology (Baltimore, Md.)]] |volume=31 |issue=2 |pages=469–73 |year=2000 |month=February |pmid=10655272 |doi=10.1002/hep.510310229 |url=http://dx.doi.org/10.1002/hep.510310229 |accessdate=2012-02-28}}</ref> A recent Markov model analysis estimated economic costs of $133.5 million during the lifetime of a single age cohort of children born in 2005, in the absence of vaccination. | ||
{{#widget:SchemaSnippet}} | {{#widget:SchemaSnippet}} | ||
===Vaccine Era=== | |||
With the licensure of inactivated hepatitis A vaccines by the Food and Drug Administration (FDA) during 1995-1996, hepatitis A became a disease that was not only common but also vaccine-preventable. Since 1996, and particularly since ACIP's 1999 recommendations for routine vaccination of children living in areas with consistently elevated hepatitis A rates, national hepatitis A rates have declined sharply.<ref name="pmid16014593">{{cite journal |author=Wasley A, Samandari T, Bell BP |title=Incidence of hepatitis A in the United States in the era of vaccination |journal=[[JAMA : the Journal of the American Medical Association]] |volume=294 |issue=2 |pages=194–201 |year=2005 |month=July |pmid=16014593 |doi=10.1001/jama.294.2.194 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16014593 |accessdate=2012-02-28}}</ref> The 1999 recommendations called for routine vaccination of children living in states and communities in which the average hepatitis A rate during a baseline period of 1987-1997 was >20 cases per 100,000 population, approximately twice the national average, and for consideration of hepatitis A vaccination of children in those states and communities in which the average rate during the baseline period was at least the national average.<ref>[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4812a1.htm CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37.]</ref> | |||
In 2004, a total of 5,683 cases (rate: 1.9 cases per 100,000 population) were reported, representing an estimated 24,000 acute clinical cases when underreporting is taken into account. This rate was the lowest ever recorded and was 79% lower than the previously recorded low in 1992.<ref>CDC. Hepatitis surveillance. Report no. 61. Atlanta, GA: US Department of Health and Human Services, CDC. 2006</ref> This decline is reflected in other fundamental shifts in hepatitis A epidemiology. | |||
==References== | ==References== | ||
Revision as of 19:49, 28 July 2014
|
Hepatitis A |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatitis A historical perspective On the Web |
|
American Roentgen Ray Society Images of Hepatitis A historical perspective |
|
Risk calculators and risk factors for Hepatitis A historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
Prevaccine Era
Hepatitis A epidemiology in the United States has fundamentally changed with licensure of hepatitis A vaccine and implementation of national ACIP recommendations for its use. Before vaccine licensure during 1995-1996, hepatitis A incidence was primarily cyclic, with peaks occurring every 10-15 years. In the United States, during 1980-1995, approximately 22,000-36,000 hepatitis A cases were reported annually to CDC (rate: 9.0-14.5 cases per 100,000 population), but incidence models indicate that the number of infections was substantially higher.[1][2] One such analysis estimated an average of 271,000 infections per year during 1980-1999, representing 10.4 times the reported number of cases.[1] Each year in the United States, an estimated 100 persons died as a result of acute liver failure attributed to hepatitis A.
The costs associated with hepatitis A are substantial. Surveillance data indicate that 11%-22% of persons with hepatitis A are hospitalized.[3] The average duration of work loss for adults who become ill has been estimated at 15.5 days for nonhospitalized patients and 33.2 days for hospitalized patients.[4] Estimates of the annual direct and indirect costs of hepatitis A in the United States have ranged from $300 million to $488.8 million in 1997 dollars.[5][4] A recent Markov model analysis estimated economic costs of $133.5 million during the lifetime of a single age cohort of children born in 2005, in the absence of vaccination.
Vaccine Era
With the licensure of inactivated hepatitis A vaccines by the Food and Drug Administration (FDA) during 1995-1996, hepatitis A became a disease that was not only common but also vaccine-preventable. Since 1996, and particularly since ACIP's 1999 recommendations for routine vaccination of children living in areas with consistently elevated hepatitis A rates, national hepatitis A rates have declined sharply.[6] The 1999 recommendations called for routine vaccination of children living in states and communities in which the average hepatitis A rate during a baseline period of 1987-1997 was >20 cases per 100,000 population, approximately twice the national average, and for consideration of hepatitis A vaccination of children in those states and communities in which the average rate during the baseline period was at least the national average.[7]
In 2004, a total of 5,683 cases (rate: 1.9 cases per 100,000 population) were reported, representing an estimated 24,000 acute clinical cases when underreporting is taken into account. This rate was the lowest ever recorded and was 79% lower than the previously recorded low in 1992.[8] This decline is reflected in other fundamental shifts in hepatitis A epidemiology.
References
- ↑ 1.0 1.1 Armstrong GL, Bell BP (2002). "Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization". Pediatrics. 109 (5): 839–45. PMID 11986444. Retrieved 2012-02-28. Unknown parameter
|month=ignored (help) - ↑ CDC. Hepatitis surveillance. Report no. 61. Atlanta, GA: US Department of Health and Human Services, CDC. 2006
- ↑ CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37
- ↑ 4.0 4.1 Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M (2000). "The cost of hepatitis A infections in American adolescents and adults in 1997". Hepatology (Baltimore, Md.). 31 (2): 469–73. doi:10.1002/hep.510310229. PMID 10655272. Retrieved 2012-02-28. Unknown parameter
|month=ignored (help) - ↑ CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37
- ↑ Wasley A, Samandari T, Bell BP (2005). "Incidence of hepatitis A in the United States in the era of vaccination". JAMA : the Journal of the American Medical Association. 294 (2): 194–201. doi:10.1001/jama.294.2.194. PMID 16014593. Retrieved 2012-02-28. Unknown parameter
|month=ignored (help) - ↑ CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1-37.
- ↑ CDC. Hepatitis surveillance. Report no. 61. Atlanta, GA: US Department of Health and Human Services, CDC. 2006